Of note, a study based on a large diabetic cohort of 113,051 T2DM patients showed that DPP-4 inhibitors as a second- or third-line add-on treatment provided CV benefits and posed no increased risks for HF, hypoglycemia, or death (45). Here, DPP4 is linked to hydrops fetalis.